Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628972 | 0.88 | AR (0.50) | PGRAR | |
| SCHEMBL633929 | 0.87 | AR (0.88) | PGRAR | |
| SCHEMBL891248 | 0.85 | AR (0.49) | PGRAR | |
| SCHEMBL631620 | 0.85 | AR (0.49) | PGRAR | |
| SCHEMBL630482 | 0.85 | AR (0.49) | PGRAR | |
| SCHEMBL630765 | 0.85 | AR (0.49) | PGRAR | |
| SCHEMBL629841 | 0.85 | AR (0.49) | PGRAR | |
| SCHEMBL890915 | 0.84 | AR (0.49) | PGRAR | |
| SCHEMBL890874 | 0.84 | AR (0.46) | PGRAR | |
| SCHEMBL629084 | 0.83 | AR (0.47) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710091-B2 | Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2419410-B1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA SAS (FR) | 2013-03-06 | — | — | EP | disclosed |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-04-05 | — | — | US | disclosed |
| EP-2419410-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119193-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | MKI67, CCND2, CCND1 | PGR 765/4885AR 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.